NCT01092611

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 190 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this long-term follow-up study is to assess the long-term health status of HIV-infected subjects who previously participated in GSK-sponsored trials evaluating the investigational HIV vaccine 732462. This study will provide additional data concerning the long-term benefits/risks associated with vaccination. No vaccine will be administered during the study period. Vaccines were administered during the primary studies.

Detailed description

General information on the health of the subject and persistence of the cellular and humoral immune responses to study vaccination will be evaluated.

Conditions

• AIDS

Interventions

Type	Name	Description
PROCEDURE	Blood collection	Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
BIOLOGICAL	GSK HIV vaccine 732462	No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.

Timeline

• Start date: 2010-03-22
• Primary completion: 2014-03-17
• Completion: 2014-05-19
• First posted: 2010-03-25
• Last updated: 2018-03-02

Locations

41 sites across 4 countries: United States, France, Germany, Spain